Akumin — Merger or Acquisition (June 2021)
15 slides from Akumin's merger presentation, Jun 25, 2021
Slide 1: Analyst Presentation
ANALYST PRESENTATION June 25, 2021 NASDAQ / TSX: AKU
Slide 2: Forward-looking Information Disclaimer
Forward-looking Information This report contains or incorporates by reference “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities laws. Forward-looking statements describe our future plans, strategies, expectations and objectives, and ar
Slide 3: Alliance Healthcare Services
Alliance Healthcare Services Founded in 1983 More than 35 years of delivering exceptional care Serving patients in: 45 States Over 1,000 Health system, Hospital Customers 19 Independent Radiology Centers 34 Oncology Centers ~ 2,500 team members 3 PRESENTATION BY AKUMIN STRICTLY PRIVATE AND CONFIDENT
Slide 4: Acquisition Strategic Rationale
Combined Acquisition Enterprise Strategic Rationale A national partner of choice for health systems and Health System / Hospital hospitals with comprehensive Services solutions addressing all their outpatient radiology and oncology needs A leading provider of: Radiology Oncology Customer base of 1,0
Slide 5: Complementary Skills and Expertise
Complementary Skills and • Outpatient care focus for all Expertise health systems, hospitals in response to industry pressures Together, we can apply our respective expertise to • Clinical delivery standardization enhance patient experience Together we to increase productivity and and outcomes, whil
Slide 6: Investment Highlights of Akumin Pro Forma
Investment 1 Comprehensive radiology and oncology solutions provider in the U.S. Highlights of Well-positioned for innovative growth in essential healthcare Akumin 2 services industries Pro Forma 3 Diversified revenue base across multiple services, health systems, in-network payors, and geographies
Slide 7: Akumin Pro Forma
Akumin Pro Forma National provider of essential radiology and oncology services in the U.S. Pro Forma: $730 million Revenue (LTM Mar-21) $210 million Adj. EBITDA* (LTM Mar-21) 1,000 Health System and Hospital Customers 154 Radiology Centers (Independent Freestanding) 34 Oncology Centers 7 PRESENTATI
Slide 8: Favorable Industry Drivers U.S. Outpatient Industry
Favorable U.S. Outpatient Industry Industry Drivers RADIOLOGY ONCOLOGY Estimated Market Size ~$17 billion ~$3 billion Aging population and population growth should Annual Growth Rate Low Single Digits Mid Single Digits drive consistent demand Number of Outpatient Centers >6,500 >2,300 for these esse
Slide 9: Diversified Revenue Base
Offering Mix Payor Mix Diversified (% of Revenue) (% of Revenue) Revenue Base 1% 7% 8% 20% Diversified offering mix across multiple modalities 52% and geographies 32% 80% Diversified payor mix with no material revenue Health Systems/Hospitals Comme rcial concentration in any health Radiology Oncolog
Slide 10: Partner of Choice for Health Systems
Partner of Radiology & Oncology Choice for Health Systems Health systems and hospitals seeking best-in-class partners to enable capital efficient network and to expand their U.S. essential outpatient Single Segment radiology and oncology services • 25 of the 30 largest U.S. health systems are custom
Slide 11: Innovative Growth
Innovative 1. Organic revenue growth Growth • Same customer or center volume growth • New contracts with existing customers • Imaging-guided therapies The combined company 2. New Wholesale Services Opportunities would be a platform that enables innovative • Combined business customer base of health
Slide 12: Culture Driven by "Deep" Integration
Culture Driven Operating Philosophy by “Deep” Integration Akumin’s value creation is driven by deep operational In-clinic Experience integration of all acquisitions Integration based on a Business Analytics culture of innovation and standardization of processes The combined enterprise will Clinical
Slide 13: Consumer Driven Brand Development
Consumer Driven Brand Development Both Akumin and Alliance brands share the same values in terms of having the consumer or patient at the heart of the strategy Brands are ultimately defined by the consumer • Expertise in independent • Expertise with health freestanding centers systems outsourcing ex
Slide 14: Pro Forma Capital Structure
*US$ millions, unless noted As at Pro (1) Pro forma vs. Q1 2021 Forma Today Pro Forma Share Price (5-day vwap) (in dollars) $ 2.98 $ 2.98 (2) Total Shares O/S (mm) 71.2 88.9 1.25x Capital Equity Value $ 212.2 $ 264.9 Structure Senior Notes due 2025 $ 466.9 $ 466.9 Alternative Financing $ - $ 500.0 (
Slide 15: Thank You!
Thank You! NASDAQ / TSX: AKU akumin.com